TECX News & Events

Tectonic Therapeutic announced it has appointed Francois Nader as an independent director to its board of directors, effective April 1, at which time he will also assume the role of chair of the board. Upon Nader assuming the role as independent director to the board of directors, Terry McGuire will resign from his role as chair of the board, a role which Nader will immediately assume. In order to provide for a smooth leadership transition, McGuire will remain a member of the board of directors until Tectonic's 2026 annual meeting of stockholders, which is anticipated to be in June.

"Our team continued to advance our lead asset TX45 with the positive topline data from Part B of our Phase 1b study in patients with HFrEF. Following our recent presentation of the full Part A data set at the ESC Heart Failure 2025 Congress, the improvements demonstrated in both left heart function and pulmonary hemodynamics across both PH-HFrEF and PH-HFpEF populations suggest TX45 has the potential to be effective in a broad patient population," said Alise Reicin, M.D., President and Chief Executive Officer of Tectonic. "Enrollment continues in our global APEX Phase 2 trial in PH-HFpEF, and we expect to report topline results from that study in 2026."